VIR Stock Analysis: Vir Biotechnology | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.912m USD | 12M Return: 71.7% | US92764N1028 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 22.8M
Qual. Beats: 0
Rev. Trend: -9.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Vir Biotechnology is a clinical-stage biopharmaceutical company developing therapeutics for serious infectious diseases and cancer. Its pipeline targets hepatitis delta virus (HDV) and solid tumors, with preclinical work on influenza A/B antibodies, antibody drug conjugates, coronavirus monoclonal antibodies, and PRO-XTEN dual-masked T-cell engagers. The company maintains a partnership-heavy business model, with collaboration and license agreements with entities including Alnylam Pharmaceuticals, GlaxoSmithKline Biologicals, the Gates Foundation, and Xencor, among others. As a clinical-stage biotech with no marketed products yet, Vir relies on these partnerships and grant funding to support R&D. Incorporated in 2016 and headquartered in San Francisco, Vir trades on NASDAQ under the ticker VIR and is classified within the Health Care / Biotechnology sub-industry.
- HDV therapy clinical trial readouts near-term stock catalysts
- GSK and Alnylam collaboration milestones offset cash burn
- PRO-XTEN solid tumor platform expands oncology pipeline valuation
- COVID antibody program faces uncertain commercial demand
| Net Income: -251.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA 22.75 > 1.0 |
| NWC/Revenue: 157.9% < 20% (prev 3.32k%; Δ -3.16k% < -1%) |
| CFO/TA -0.17 > 3% & CFO -202.5m > Net Income -251.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (168.9m) vs 12m ago 21.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 25.19% > 50% (prev 1.59%; Δ 23.60% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.39 (Total Current Assets 573.7m - Total Current Liabilities 95.0m) / Total Assets 1.21b |
| B: -1.02 (Retained Earnings -1.24b / Total Assets 1.21b) |
| C: -0.23 (EBIT TTM -279.5m / Avg Total Assets 1.20b) |
| D: 4.23 (Book Value of Equity 982.5m / Total Liabilities 232.3m) |
| Altman-Z'' = 2.13 = BBB |
| DSRI: 0.26 (Receivables 21.9m/5.20m, Revenue 303.2m/19.0m) |
| GMI: 0.37 (GM 35.21% / 96.20%) |
| AQI: 1.57 (AQ_t 0.44 / AQ_t-1 0.28) |
| SGI: 15.96 (Revenue 303.2m / 19.0m) |
| TATA: -0.04 (NI -251.7m - CFO -202.5m) / TA 1.21b) |
| Beneish M = 6.86 (Cap -4..+1) = D |
As of October 18, 2026, the stock is trading at USD 9.96 with a total of 1,735,243 shares traded. Over the past week, the price has changed by -14.87%, over one month by -5.32%, over three months by +5.96% and over the past year by +71.72%.
Current recommended Stop Loss: 8.10 (which is 18.7% or 2.9 ATR below the current price).
Vir Biotechnology has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy VIR.
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21 | 110.8% |
P/E Forward = 4.2717
P/S = 6.306
P/B = 1.9118
Revenue TTM = 303.2m USD
EBIT TTM = -279.5m USD
EBITDA TTM = -268.0m USD
Long Term Debt = 84.1m USD (estimated: total debt 93.3m - short term 9.14m)
Short Term Debt = 9.14m USD (from shortTermDebt, last quarter)
Debt = 93.3m USD (from shortLongTermDebtTotal, last quarter) (leases 93.3m already included)
Net Debt = -435.3m USD (calculated: Debt 93.3m - CCE 528.6m)
Enterprise Value = 1.48b USD (1.91b + Debt 93.3m - CCE 528.6m)
Interest Coverage Ratio = unknown (Ebit TTM -279.5m / Interest Expense TTM 0.0)
EV/FCF = -7.43x (Enterprise Value 1.48b / FCF TTM -198.8m)
FCF Yield = -13.46% (FCF TTM -198.8m / Enterprise Value 1.48b)
FCF Margin = -65.55% (FCF TTM -198.8m / Revenue TTM 303.2m)
Net Margin = -83.00% (Net Income TTM -251.7m / Revenue TTM 303.2m)
Gross Margin = unknown ((Revenue TTM 303.2m - Cost of Revenue TTM 11.5m) / Revenue TTM)
Tobins Q-Ratio = 1.22 (Enterprise Value 1.48b / Total Assets 1.21b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 93.3m)
Taxrate = 0.22% (179k / 80.3m)
NOPAT = -278.8m (EBIT -279.5m * (1 - 0.22%)) [loss with tax shield]
Current Ratio = 6.04 (Total Current Assets 573.7m / Total Current Liabilities 95.0m)
Debt / Equity = 0.09 (Debt 93.3m / totalStockholderEquity, last quarter 982.5m)
Debt / EBITDA = 1.62 (negative EBITDA) (Net Debt -435.3m / EBITDA -268.0m)
Debt / FCF = 2.19 (negative FCF - burning cash) (Net Debt -435.3m / FCF TTM -198.8m)
Total Stockholder Equity = 839.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.91% (Net Income -251.7m / Total Assets 1.21b)
RoE = -29.99% (Net Income TTM -251.7m / Total Stockholder Equity 839.2m)
RoCE = -30.27% (EBIT -279.5m / Capital Employed (Equity 839.2m + L.T.Debt 84.1m))
RoIC = -25.03% (negative operating profit) (NOPAT -278.8m / Invested Capital 1.11b)
WACC = 11.43% (E(1.91b)/V(2.01b) * Re(11.99%) + D(93.3m)/V(2.01b) * Rd(0.0%) * (1-Tc(0.00)))
Discount Rate = 11.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 72.17 | Cagr: 10.36%
[DCF] Fair Price = unknown (Cash Flow -198.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.72 | # QB: 0
Revenue Correlation: -9.82 | Revenue CAGR: -8.63% | SUE: 0.37 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.73 | Chg30d=+0.00% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=-1.76 | Chg30d=+0.00% | Revisions=-57% | GrowthEPS=+44.5% | GrowthRev=+257.7%
EPS next Year (2027-12-31): EPS=-2.49 | Chg30d=+0.00% | Revisions=-17% | GrowthEPS=-41.7% | GrowthRev=-69.0%
[Analyst] Revisions Ratio: -36% (up=3, down=8)